痰热清联合阿奇霉素治疗小儿支原体肺炎的临床效果分析

Analysis on clinical efficacy of Tanreqing injection combined with azithromycin sequential therapy in children with mycoplasma pneumonia

目的探讨痰热清联合阿奇霉素治疗小儿支原体肺炎的临床疗效。方法将我科收治的168例小儿支原体肺炎患者，随机分为对照组和治疗组，各84例，对照组只给予阿奇霉素治疗，治疗组在阿奇霉素基础上加用痰热清注射液，比较其临床疗效。结果治疗组患儿的主要临床症状包括发热、咳嗽、肺部干湿罗音消失时间明显短于对照组，差异具有显著性（P〈0．05），观察组总有效率为98．2％，痊愈率为82．7％，对照组总有效率为95．2％，治愈率为44．0％，两组总有效率相近，不具有统计学差异（P〉0．05），治愈率差异具有显著性（P〈0．05）治疗后观察组CD4＋、CD4＋／CD8＋分别是（36．86±4．96）％，（1．27±0．38），明显高于对照组（32．05±4．56）％，（1．08±0．22），差异有显著性（P〈0．05）。结论痰热清联合阿奇霉素治疗小儿支原体肺炎能够明显缩短患儿临床病程，减少患儿痛苦，治愈率高，临床疗效确切。

Objective To observe the curative effect of Tanreqing injection combined with azithromycin in children with mycoplasma pneumonia. Methods 168 cases of children with mycoplasma pneumonia were randomly divided into control group and observation group, with 84 cases for each group. Azithromycin sequential therapy was performed in control group, while Tanreqing injection combined with azithromycin sequential therapy was given to children of observation group. The clinical effects and recovery time of pathogenetic condition were observed. Results The cure rate of observation group （82.4%） was higher than that in control group （54.4%）, the difference was statistically significant （P〈0.05）. The total effective rate was similar, the difference was not statistically significant （P〉0.05） CD4＋, CD4＋ / CD8＋ in control group [（36.86 ±4.96）%, （1.27 ± 0.38）]were obviously lower than those in observation group [（32.05 ±4. 56） %, （1.08±0.22）], the differences were statistically significant （P〈0.05）.Conclusion Tanreqing injection combined with azithromycin can improve the clinical efficacy in children with mycoplasma pneumonia significantly.